EGFR and non-small cell lung carcinoma: In a meta-analysis of six randomized trials involving NSCLC patients who had not previously received treatment, the median PFS for patients using EGFR-TKI (gefitinib or erlotinib) was 11.0 months, compared with only 5.6 months in the chemotherapy group (Lee et al., 2017).